ASX:JHL

Stock Analysis Report

Executive Summary

Jayex Healthcare Limited develops healthcare industry service technologies and integrated dispensing automation systems for the pharmaceutical and healthcare sectors in Australia and the United Kingdom.


Snowflake Analysis

Overvalued with worrying balance sheet.

Share Price & News

How has Jayex Healthcare's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: JHL's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0%

JHL

10.2%

AU Healthcare Services

2.8%

AU Market


1 Year Return

-62.5%

JHL

26.5%

AU Healthcare Services

-16.2%

AU Market

Return vs Industry: JHL underperformed the Australian Healthcare Services industry which returned 27.7% over the past year.

Return vs Market: JHL underperformed the Australian Market which returned -19.1% over the past year.


Shareholder returns

JHLIndustryMarket
7 Day0%10.2%2.8%
30 Day0%7.7%-15.2%
90 Dayn/a-15.8%-23.4%
1 Year-62.5%-62.5%27.1%26.5%-12.4%-16.2%
3 Year-50.0%-50.0%87.4%83.6%-0.2%-13.9%
5 Yearn/a324.6%288.2%11.5%-13.6%

Price Volatility Vs. Market

How volatile is Jayex Healthcare's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Jayex Healthcare undervalued compared to its fair value and its price relative to the market?

0.55x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate JHL's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate JHL's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: JHL is unprofitable, so we can't compare its PE Ratio to the Healthcare Services industry average.

PE vs Market: JHL is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate JHL's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: JHL is good value based on its PB Ratio (0.5x) compared to the AU Healthcare Services industry average (2.7x).


Next Steps

Future Growth

How is Jayex Healthcare forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

34.9%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Jayex Healthcare has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Jayex Healthcare performed over the past 5 years?

24.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: JHL is currently unprofitable.

Growing Profit Margin: JHL is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: JHL is unprofitable, but has reduced losses over the past 5 years at a rate of 24.5% per year.

Accelerating Growth: Unable to compare JHL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: JHL is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (12.8%).


Return on Equity

High ROE: JHL has a negative Return on Equity (-23.07%), as it is currently unprofitable.


Next Steps

Financial Health

How is Jayex Healthcare's financial position?


Financial Position Analysis

Short Term Liabilities: JHL's short term assets (A$2.9M) do not cover its short term liabilities (A$5.1M).

Long Term Liabilities: JHL's short term assets (A$2.9M) do not cover its long term liabilities (A$4.3M).


Debt to Equity History and Analysis

Debt Level: JHL's debt to equity ratio (104.2%) is considered high.

Reducing Debt: JHL had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: JHL has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: JHL has less than a year of cash runway if free cash flow continues to grow at historical rates of 4.9% each year.


Next Steps

Dividend

What is Jayex Healthcare's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate JHL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate JHL's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if JHL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if JHL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of JHL's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.9yrs

Average management tenure


CEO

Nick Fernando

2.92s

Tenure

AU$436,202

Compensation

Mr. Nick Fernando has been the Chief Executive Officer of Jayex Healthcare Limited since May 23, 2017. Mr. Fernando has been Managing Director at Jayex Technology Limited at Jayex Healthcare Limited since  ...


CEO Compensation Analysis

Compensation vs Market: Nick's total compensation ($USD262.12K) is about average for companies of similar size in the Australian market ($USD238.47K).

Compensation vs Earnings: Nick's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Michael Boyd
Executive Chairmanno dataAU$60.00kno data
Nick Fernando
Chief Executive Officer2.92yrsAU$436.20kno data
Nathan Woodard
Chief Financial Officer1.67yrsAU$146.87kno data
Melanie Jaye Leydin
Company Secretary4.67yrsno datano data

2.9yrs

Average Tenure

Experienced Management: JHL's management team is considered experienced (2.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Jayex Healthcare Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Jayex Healthcare Limited
  • Ticker: JHL
  • Exchange: ASX
  • Founded: 2006
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: AU$2.645m
  • Shares outstanding: 176.36m
  • Website: https://www.jayex.com/en-au/

Number of Employees


Location

  • Jayex Healthcare Limited
  • 17B Cribb Street
  • Milton
  • Queensland
  • 4064
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
JHLASX (Australian Securities Exchange)YesOrdinary SharesAUAUDDec 2015
JHLCHIA (Chi-X Australia)YesOrdinary SharesAUAUDDec 2015

Biography

Jayex Healthcare Limited develops healthcare industry service technologies and integrated dispensing automation systems for the pharmaceutical and healthcare sectors in Australia and the United Kingdom. The company offers Jayex Connect platform, a cloud-based patient engagement platform, which provides appointment booking, patient calling, patient check-in, health messaging, and script management solutions. Jayex Healthcare Limited was founded in 2006 and is based in Milton, Australia. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/06 10:51
End of Day Share Price2020/04/03 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.